GOSS · Gossamer Bio, Inc. · Executive Compensation
$9.28
-0.17 (-1.80%)
At close · Nov 3
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.75M
Shares
6.11M
Volume · Nov 3
139.45K
Avg daily vol (38 sessions)
273.69K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $2,300,455 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $1,253,431 |
| Robert Smith | Chief Commercial Officer | $1,180,744 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $2,005,432 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $1,171,904 |
| Richard Aranda | Chief Medical Officer | $1,065,055 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $2,095,988 |
| Robert Smith | Chief Commercial Officer | $1,330,845 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $1,287,882 |
| Richard Aranda | Chief Medical Officer | $1,032,753 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $7,262,410 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $3,268,699 |
| Richard Aranda | Chief Medical Officer | $2,481,944 |
| Chief Commercial | Officer | — |
| Robert Smith | Chief Commercial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $4,751,620 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $2,825,437 |
| Christian Waage | Executive Vice President, Technical Operations and Administration | $1,650,988 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Sheila Gujrathi | Former President and Chief Executive Officer | $7,213,742 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $2,014,958 |
| Luisa Salter-Cid | Chief Scientific Officer | $1,994,828 |
| Christian Waage | Executive Vice President, Technical Operations and Administration | $1,990,351 |
| Jakob Dupont | Former Chief Medical Officer | $1,642,287 |
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $598,771 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sheila Gujrathi | Former President and Chief Executive Officer | $6,245,606 |
| Bryan Giraudo | Chief Operating Officer and Financial Officer | $2,647,282 |
| Luisa Salter-Cid | Chief Scientific Officer | $2,258,884 |
| Christian Waage | Executive Vice President, Technical Operations and Administration | $2,060,653 |
| Jakob Dupont | Former Chief Medical Officer | $1,637,440 |
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $982,222 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Faheem Hasnain | Chairman, President and Chief Executive Officer | $18,709,912 |
| Sheila Gujrathi | Former President and Chief Executive Officer | $18,709,912 |
| Jakob Dupont | Former Chief Medical Officer | $3,530,454 |
| Bryan Giraudo | Chief Financial Officer | $2,192,515 |
| Luisa Salter-Cid | Chief Scientific Officer | $1,858,327 |
| Christian Waage | Executive Vice President and General Counsel | $867,304 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gregory A. Ciongoli | Class III director | Appointed | 2026-09-16 |
| Steven Nathan, M.D. | Class I director | Appointed | 2024-03-12 |
| Skye Drynan | Class III director | Appointed | 2024-03-12 |
| John Quisel, J.D., Ph.D. | Class III director | Appointed | 2023-11-29 |
| Kristina Burow | Board of Directors | Resigned | 2023-09-07 |
Leadership
- Faheem Hasnain CEO, Chairman
- Bryan Giraudo CFO, COO
- Christian Waage General Counsel
- Gregory A. Ciongoli Board Member
- John Quisel Board Member
- John Quisel, J.D., Ph.D. Board Member
- Russell Cox Board Member
- Sandra Milligan Board Member
- Sandra Milligan, M.D., J.D. Board Member
- Skye Drynan Board Member
- Steven Nathan Board Member
- Steven Nathan, M.D. Board Member
- Thomas Daniel Board Member
Key facts
CIK
1728117
CUSIP
38341P201
13F (30d)
20 filings
13 filers
Visit website
Investor relations